Work

O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.05.807

Authors: J. Ajani, F. El Hajbi, D. Cunningham, M. Alsina, P. Thuss-Patience, G. Scagliotti, M. Van den Eynde, I. Rybkin, L. Shen, K. Kato, S. Kim, S. D’Alonzo, W. Yu, A. Tao, E. Van Cutsem

Institutions: The University of Texas MD Anderson Cancer Center, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Stiftung Charité, Charité – Universitätsmedizin Berlin, University of Turin, Cliniques Universitaires Saint-Luc, UCLouvain, Henry Ford Hospital, Peking University Cancer Hospital, National Cancer Center Hospital, Asan Medical Center, University of Ulsan, BeiGene (China), Universitair Ziekenhuis Leuven, KU Leuven

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: BeiGene

OpenAlex ID: W3186577795

FWCI: 1.173

Cites: 1

Cited by: 7

Related to: 10